Richman J, Ring A, Dowsett M, Sestak I, et al. Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer. Breast Cancer Res Treat 2020 Nov 21. pii: 10.1007/s10549-020-06013.
PMID: 33222093